Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1979 - Administrative law |
Other editions - View all
Common terms and phrases
accurately weighed addition to complying agar diffusion assay amended ampicillin antibiotic assay as follows batch for potency capsules chapter chlortetracycline containing approximately 300 crystallinity demeclocycline dicloxacillin digoxin dilute an aliquot dosage forms doxycycline Drug Administration drug application drug product Food and Drug Further dilute gentamicin give a stock grams hetacillin hydrochloric acid immediate containers insulin labeled in accordance less than 90 loss on drying methods of assay-(1 Microbiological agar diffusion micrograms milligrams milliliter milliliter estimated minocycline nafcillin neomycin neomycin sulfate number of milligrams nystatin oral oxytetracycline packages penicillin ples polymyxin potassium phosphate potassium phosphate buffer preparing the sample Proceed as directed purity reagent reference concentration represented to contain request shall contain Requests for certification Requirements for certification Results of tests sample for assay Samples required solution of convenient Standards of identity stock solution submitted Subpart suspension tablets tests and assays Tests and methods tetracycline tion titration volumetric flask
Popular passages
Page 82 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be, concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended,...
Page 82 - Secretary pursuant to subsection (b), do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof; (2) the results of such tests show that such drug is unsafe for use under such conditions...
Page 134 - If offered for use in arthritis, or rheumatism, in juxtaposition therewith, the statement: Caution— If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age consult a physician immediately.
Page 55 - A statement of the methods, facilities, and controls used for the manufacturing, processing, and packing of the new drug to establish and maintain appropriate standards of identity, strength, quality, and purity as needed for safety and to give significance to clinical investigations made with the drug. 6. A statement covering all information available to the sponsor derived from preclinical investigations and any clinical studies and experience with the drug as follows: a.
Page 67 - As used in this subsection and subsection (e) of this section, the term "substantial evidence" means evidence consisting of adequate and wellcontrolled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved...
Page 55 - Food and Drug Administration will be prepared to confer with the sponsor concernIng this action. b. If the drug has been marketed commercially or Investigated (eg outside the United States) , complete Information about such distribution or Investigation shall be submitted, along with a complete bibliography of any publications about the drug. c. If the drug is a combination of previously investigated or marketed drugs, an adequate summary of preexisting Information from...
Page 185 - ... of the act if shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry, or medicine not involving clinical use; or in law enforcement; or in research not involving clinical use; or in chemical analysis or physical testing, provided they are to be used only for such instruction, law enforcement, research, analysis, or testing, and provided further that their labels bear the statement "Not for drug use.
Page 78 - ... licensed by law to administer the drug can use the drug safely and for the purposes for which it is intended, including all purposes for which it is advertised or represented...
Page 57 - Ordinarily, a plan for clinical trial will not be regarded as reasonable unless, among other things, it provides for more than one independent competent investigator to maintain adequate case histories of an adequate number of subjects designed to record observations and permit evaluation of any and all discernible effects attributable to the drug in each individual treated, and comparable records on any individuals employed as controls. These records shall be individual records for each subject...
Page 111 - Warning—May be habit forming", shall immediately follow (without intervening written, printed, or graphic matter) the name by which such drug is titled in the part or panel of the label thereof which is presented or displayed under customary conditions of purchase. (d) A drug shall not be considered to be misbranded by reason of failure of its label to bear the statement...